CD34 and Alzheimer disease: Further examination of these findings revealed a dose-dependent effect of increased CD34+CD133+ cell quartiles on the reduction in AD risk among KIRREL3 rs4144611 TT or rs580382 CC homozygotes as well as in EXOC6B rs61619102 CC homozygotes (Table 6, Table S6, and Table S7).